2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
5
Recurrence
2
Esophageal Neoplasms
2
Solitary Fibrous Tumor, Pleural
1
Small Cell Lung Carcinoma
1
Recurrent Squamous Cell Lung Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pleural Effusion, Malignant
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
MET Positive
1
Lung Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
Oxaliplatin
46
Gemcitabine
45
Fluorouracil
40
Capecitabine
31
pembrolizumab
30
Leucovorin
29
Docetaxel
27
Cisplatin
25
Paclitaxel
23
Irinotecan
18
Carboplatin
18
Bevacizumab
18
130-nm albumin-bound paclitaxel
17
Radiotherapy
16
Pemetrexed
15
Albumin-Bound Paclitaxel
15
Nivolumab
13
Ramucirumab
11
Cyclophosphamide
11
Drug Therapy
9
Trastuzumab
8
Erlotinib Hydrochloride
8
zolbetuximab
7
Taxes
7
Radiosurgery
7
trastuzumab deruxtecan
6
cemiplimab
6
Blood Specimen Collection
6
regorafenib
5
durvalumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
rilotumumab
×
Clear all
NCT01443065
2020-11-17
MEGA
UNICANCER
Phase 2
Completed
162 enrolled